Latest news with #PekingUniversity
Zawya
2 days ago
- Business
- Zawya
HKSTP Brings Talent and Enterprise Recruitment Drive to Beijing
Showcasing Hong Kong's Innovation and Technology Opportunities at Tsinghua and Peking University HONG KONG SAR - Media OutReach Newswire - 2 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP) is actively expanding efforts to attract talent and enterprises to Hong Kong's innovation and technology (I&T) sector. From 18 to 20 May, HKSTP led a delegation to Beijing, engaging with local I&T companies, industry associations, and leaders from top universities to strengthen connections between the innovation ecosystems of Beijing and Hong Kong. During the visit, HKSTP also hosted several engagement sessions to introduce Hong Kong's I&T landscape to students and enterprises, aiming to inspire future entrepreneurs and professionals to consider Hong Kong for their careers and ventures. Led by the CEO of HKSTP Albert Wong, the delegation included Chief Talent Officer Fanny Wong and Head of Startup Ecosystem and Development Derek Chim. They visited Peking University and Tsinghua University, two of China's top universities, and met with college leaders and the Tsinghua Entrepreneur Network to explore collaboration in talent development, startup cultivation, and innovation resource expansion. In addition, HKSTP hosted on-campus sharing sessions at both universities, connecting with nearly 200 top students, sharing insights on Hong Kong's startup ecosystem, internship and career opportunities, and encouraging them to pursue entrepreneurial paths or professional development in the city to contribute to the national I&T advancement. HKSTP CEO Albert Wong emphasized Hong Kong's unique advantage of enjoying strong support from the Motherland and being closely connected to the world. He also noted, "Where there's talent, businesses will follow." Chief Talent Officer Fanny Wong added, "HKSTP is committed to attracting and nurturing I&T talent while building a diverse and thriving innovation ecosystem, and promoting Hong Kong as an international hub for high-calibre talents. She said, "Hong Kong plays the dual role of a 'super-connector' and 'super value-adder,' bridging global I&T resources. With world-class Research & Development (R&D) facilities and international collaboration platforms, HKSTP offers a powerful launchpad for young professionals and entrepreneurs looking to go global. Coming to Hong Kong for internships, employment or starting a business will be an important step for you to enter the international stage. Join Hong Kong's innovation and technology ecosystem and empower Hong Kong's economy and high-tech talents." HKSTP continues to maintain close ties with the Government, industry, academia, and research institutions, and co-hosted the "Seminar on Hong Kong's Science and Technology Innovation Ecosystem Empowers Mainland Enterprise to Scale globally" in Beijing, in partnership with the Hong Kong Alumni Association of Beijing Universities. Supported by the Hong Kong SAR Government's Beijing Office and InvestHK, the forum spotlighted Hong Kong's dynamic I&T ecosystem and encouraged Mainland enterprises to establish a presence in the city. The event featured keynote speeches by distinguish guests, sharing Hong Kong's development outlook and generating strong interest from the local business community. Nearly 100 participants attended, exploring potential collaboration and investment opportunities in Hong Kong. In his opening remarks, Mr. Wong highlighted Hong Kong's role in connecting the Mainland industries with the global markets and is also a critical springboard for Mainland enterprises expanding into Asia, deepening their presence along the Belt and Road Initiative, and expanding into emerging countries. He said, "The Science Park Shenzhen Branch in Futian plays the role to attract external investment and serve enterprises in going global, providing scientific research and collaboration space for innovative technology enterprises and talents, and strengthening the interaction of the global ecosystem." Mr. Wong also introduced HKSTP's vibrant I&T ecosystem, home to over 2,300 tech companies from 25 countries and regions, and more than 15,000 R&D professionals. He invited entrepreneurs and innovators to bring their ideas to Hong Kong, whether they are looking to expand internationally or set up locally and become part of HKSTP's dynamic community. HKSTP also runs a suite of talent attraction and development initiatives, including the Global Internship Programme, which offers positions in biotech, AI & data, fintech, advanced manufacturing, and more. The programme received over 1,000 applications last year, selecting 30+ outstanding international students, and has seen applications triple to nearly 3,000 this year. Additionally, the Talent Foundry initiative partners with local universities to support students in career planning and professional development, helping bridge the gap between academic skills and industry needs, while expanding the local talent pool for the innovation sector. Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at Hong Kong Science and Technology Parks Corporation
LeMonde
2 days ago
- Politics
- LeMonde
The end of the American dream for Chinese students
Few academic records are as impressive as that of Duo Yi, age 24. After graduating with honors in international relations from Peking University – China's most prestigious university – she went on to earn a master's degree at Oxford in the United Kingdom, thanks to a scholarship for the most talented students. She wanted to go even further and applied for a doctorate at Harvard Kennedy School in the United States, regarded as the world's top institution for political science. "It was the program of my dreams. I was extremely happy when I found out I had been accepted," she told Le Monde. Duo Yi received her visa a few weeks ago, but she is no longer sure if it is still valid, and now wonders, given the open hostility of the American administration toward Chinese students, whether she would be able to study in the US in peace. Two recent developments complicated her plans. First, Donald Trump's campaign against admitting foreign students to Harvard, which, even though the American president was overruled by judges, left her fearing a highly uncertain environment. Then came the statements by Secretary of State and National Security Adviser Marco Rubio, who, on Wednesday, May 28, declared that he wanted to "revoke visas for Chinese students, including those with connections to the Chinese Communist Party or studying in critical fields."
The Sun
2 days ago
- Health
- The Sun
Cancer treatment turbocharges patients' own blood cells to kill solid tumours for first time
A LIVING cancer drug has been proven to work against solid tumours for the first time. Immune-boosting CAR-T therapy removes a patient's white blood cells and engineers them into highly specialised cancer killers in a lab. 1 They are then injected back into the patient and let loose against the disease. It is currently only used for blood cell cancers like leukaemia but research by Peking University in China has found it can also work against tumours that form as lumps. In a study of 266 people with stomach cancer, patients who received the treatment survived an average of 7.9 months compared to 5.5 months without it. It took 3.3 months for their cancer to worsen, compared to 1.8 months without. Study author Dr Changsong Qi said the results showed a 'significant increase in progression-free survival and clinically meaningful increase in overall survival'. More than 90 per cent of cancers are solid tumours that grow as a physical mass, including the big four of bowel, breast, lung and prostate. The findings raise the hope that tens or even hundreds of thousands more patients will one day benefit from the pioneering approach using their own immune systems instead of harsh drugs. 'Groundbreaking milestone' Dr Carl June, of the University of Pennsylvania, is credited with inventing the therapy and commented: 'This is a groundbreaking milestone for the field of CAR-T therapies against solid tumours.' CAR-T therapy, full name chimeric antigen receptor T-cell therapy, is an advanced type of immunotherapy that turbocharges the body's own defences to fight off cancer. It is intended to be more accurate and cause less collateral damage and side effects by only attacking cancerous cells and not healthy ones. Sun Health Explainer: What is cancer? Young Sunderland fan Bradley Lowery took part in a major clinical trial of it in 2017 before dying from neuroblastoma aged six. It is currently available on the NHS in England for certain types of leukaemia and lymphoma. More than 650 forms of the treatment are now in development for solid cancers. Dr John Haanen, from the Netherlands Cancer Institute, said: 'There is clearly now evidence that this treatment can benefit patients with solid cancers. It is an important development.' The study was published in The Lancet and presented at the conference of the American Society for Clinical Oncology. Dr Catherine Elliott, of Cancer Research UK, said: 'This is an encouraging early sign and further trials will now be needed.'
Yahoo
3 days ago
- Business
- Yahoo
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-based chemotherapy for treatment-naive patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The results were featured in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO is recognized as the world's most prestigious oncology conference, serving as a global stage for unveiling transformative scientific and clinical advancements. The Oral Sessions are highly competitive, served for studies demonstrating significant clinical relevance or scientific innovation. In 2025, ASCO received a record-breaking 7,775 abstract submissions, with 32 Chinese-led studies selected for oral presentation - among them, the LBL-024 trial (NCT06157827). The study, led by Professor Shen Lin of Peking University Cancer Hospital and conducted across multiple clinical centers, evaluates the efficacy and safety of LBL-024 combined with etoposide plus platinum-based chemotherapy as a first-line treatment for advanced EP-NEC. Robust Anti-Tumor Activity Observed with LBL-024 Plus Chemotherapy In 52 efficacy-evaluable patients, the overall response rate (ORR) across all dose levels was 75.0% and the disease control rate (DCR) was 92.3%, significantly outperforming historical ORR data (30%-55%) with chemotherapy alone. The 15 mg/kg in dose optimization demonstrated the strongest anti-tumor activity, achieving an ORR of 83.3% and a DCR of 100%. 57.7% (30/52) of the patients experienced >50% tumor shrinkage. As of April 15th, 2025, with a median follow-up of 8.2 months, progression-free survival (PFS) data remains immature, but trends indicate promising durability across all the dose groups. In the phase Ib dose escalation stage, no dose-limiting toxicities (DLTs) were observed. Most treatment-emergent adverse events (TEAEs) were Grade 1–2 and manageable, primarily associated with chemotherapy, including hematologic toxicity and nausea. No unexpected safety signals were identified. Leadership Perspectives Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated:" We are thrilled to share these exciting clinical data, which strongly support the advancement of LBL-024 into a pivotal phase III trial as a first-line treatment for EP-NEC. Our strategy prioritizes efficient development through single-arm registrational trial in underserved indications, while also maximizing value through broad indication expansion. LBL-024 received regulatory clearance in April 2024 to initiate a single-arm pivotal trial in China, marking the first 4-1BB targeted agent globally to reach this stage. With its expanded use now demonstrated in first-line settings and active studies in cancers such as SCLC and NSCLC, LBL-024 is poised to offer promising transformative therapeutic options for more cancer patients worldwide." Dr. Xiaoqiang Kang, Founder, Chairman and CEO of Leads Biolabs, added, "It is deeply encouraging to see LBL-024 featured consecutively in ASCO oral presentations. From target selection to molecular design, our R&D approach has focused on differentiated innovation to address pressing clinical challenges. The success of LBL-024 reflects our commitment to pioneering innovation at the source—breaking free from homogeneity to deliver genuinely impactful therapies. We remain dedicated to addressing unmet needs, advancing breakthrough therapeutics, and improving outcomes for patients across the globe." About LBL-024 LBL-024 is a potential first-in-class bispecific antibody simultaneously targeting PD-L1 and the co-stimulatory receptor 4-1BB. It is the first 4-1BB-targeting bispecific antibody globally to reach the single arm pivotal trial stage as a monotherapy and holds promise to become the first approved treatment specifically for extrapulmonary neuroendocrine carcinoma (EP-NEC), a malignancy with significant unmet medical need. Developed using Leads Biolabs' proprietary X-Body™ bispecific platform, LBL-024 features a 2:2 format with two binding domains each for PD-L1 and 4-1BB, and an optimized affinity ratio. This design allows LBL-024 to both reverse PD-L1–mediated immune suppression and selectively enhance T cell activation, resulting in potent, synergistic anti-tumor effects. In Phase I/II clinical trials in China, LBL-024 has demonstrated promising efficacy and a favorable safety profile in patients with advanced EP-NEC, both as monotherapy and in combination with chemotherapy. The lack of a standard of care in EP-NEC supports the pursuit of accelerated approval through a single-arm pivotal study. In recognition of its clinical potential, LBL-024 received Breakthrough Therapy Designation (BTD) from the National Medical Products Administration (NMPA) in China (October 2024), and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for neuroendocrine carcinoma (November 2024). Beyond NEC, LBL-024 has shown encouraging early activity in other tumor types, including small cell lung cancer (SCLC), ovarian cancer (OC), biliary tract cancer (BTC), and with strong potential for expansion into broader indications such as non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and gastric cancer (GC). About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally. We are a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 12 innovative drug candidates, including six clinical-stage drug candidates, of which four lead products are among the top-tier clinically advanced candidates globally. We adopt a science-driven R&D approach and have successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. We have also developed multiple proprietary technology platforms, including LeadsBodyTM platform (a CD3 T-cell engager platform), X-bodyTM platform (a 4-1BB engager platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of our bispecific antibody portfolios. We have established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of our drug candidates, coupled with our global perspectives, proactive strategy, and efficient clinical validation, have made us an attractive partner for leading industry players and venture capitals. For more information, please visit View original content: SOURCE Leads Biolabs
Forbes
3 days ago
- General
- Forbes
Rocks Date Onset Of Modern Plate Tectonics To 2 Billion Years
When plate tectonics first emerged on Earth is still debated. Some models suggest that Earth at first possessed a single protoplate covering the entire planet. This protoplate eventually broke open, the fragments forming tectonic plates. Other models suggest plate tectonics may have evolved gradually over billions of years. A new study, Xiaoli Li and colleagues from the Earth and Space Sciences Department, Peking University, published evidence from the petrologic record suggesting that the modern style plate tectonics begun in the Paleoproterozoic — over 1.6 billion years ago. The team analyzed eclogites from the Belomorian Province in Baltica. Eclogite is a metamorphic rock containing red almandine-pyrope garnet hosted in a matrix of green omphacite (a sodium-rich pyroxene). Eclogites typically results from high to ultrahigh pressure metamorphism of basaltic lava at low thermal gradients as it is subducted to the lower crust to upper mantle depths in a subduction zone. Subduction zones, where one tectonic plate slides beneath another plate, are a key element of modern plate tectonics. Radiometric dating of the rocks revealed an age around 2 and 1.8 billion years ago, making them the oldest known subduction eclogites. The protolith, the original lava rock, is even older with an age ranging between 2.7 and 2.5 billion years. The eclogite from Baltica shows some chemical similarities to 'modern' eclogite, formed just 65 million years ago, from the Himalayas. The Himalaya orogen formed when the former ocean between Asia and India was subducted, and remains of oceanic crust and continental fragments were uplifted by the collision. The authors suggest that in a similar way the eclogite from Baltica demonstrates the existence of a mountain range, comparable to the Himalaya range, on the supercontinent Columbia over two billion years ago. Plate tectonics has, so far, only been observed on Earth, and may be essential to making a world hospitable for life by constantly remixing and renewing the outer layers of the planet. The new results, together with previous research, suggests that something happened around 3.8 to 2 billion years ago, with Earth switching from a single plate towards plate tectonics and changing its geological evolution forever. The study,"Orosirian cold eclogite from Baltica marks the onset of modern plate tectonics," was published in the journal Earth and Planetary Science Letters.
